By harnessing the potential of the innate immune system, we are developing ground breaking NK cell and small molecule therapies. Learn More at NK:IO.
Location: United Kingdom, England, London
Investors 1
| Date | Name | Website |
| 07.06.2024 | Cambridge ... | cambridgea... |
Mentions in press and media 3
| Date | Title | Description |
| 25.07.2023 | NK:IO Raises £1.2M in Funding | NK:IO, a London, UK-based company which specializes in natural killer (NK) cell biology applied to the development of off-the-shelf cell therapies targeting solid tumours, raised £1.2M in funding. The round, which brought the total amount t... |
| 25.07.2023 | NK:IO raises £1.2M, bringing total Seed funding to £5.1M, to advance pioneering NK cell therapy | NK:IO, a leader in natural killer (NK) cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumours, has raised £1.2M. This brings total equity financing to £3.2M and will enable the ... |
| - | NK:IO | “By harnessing the potential of the innate immune system, we are developing ground breaking NK cell and small molecule therapies. Learn More at NK:IO.” |